Identification

Name
Thiethylperazine
Accession Number
DB00372  (APRD00323)
Type
Small Molecule
Groups
Withdrawn
Description

A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)

Structure
Thumb
Synonyms
  • 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
  • Norzine
  • Thiethylperazin
  • Thiéthylpérazine
  • Thiethylperazine
  • Thiethylperazinum
  • Tietilperazina
External IDs
GS 95 / NSC 130044
Product Ingredients
IngredientUNIICASInChI Key
Thiethylperazine malateHP46XK89XB 52239-63-1GTHHLZDYRHLACN-UHFFFAOYSA-N
Thiethylperazine maleateRUK64CF26E 1179-69-7RVBRTNPNFYFDMZ-SPIKMXEPSA-N
International/Other Brands
Torecan (Krka)
Categories
UNII
8ETK1WAF6R
CAS number
1420-55-9
Weight
Average: 399.616
Monoisotopic: 399.180289323
Chemical Formula
C22H29N3S2
InChI Key
XCTYLCDETUVOIP-UHFFFAOYSA-N
InChI
InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3
IUPAC Name
2-(ethylsulfanyl)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN2CCN(C)CC2)C=C1

Pharmacology

Indication

For the treatment or relief of nausea and vomiting.

Structured Indications
Not Available
Pharmacodynamics

Thiethylperazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, Thiethylperazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.

Mechanism of action

Thiethylperazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Thiethylperazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Thiethylperazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with thiethylperazine.

TargetActionsOrganism
UD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

60%

Metabolism
Not Available
Route of elimination

Thiethylperazine is eliminated in the urine.

Half life
Not Available
Clearance
Not Available
Toxicity

Manifestations of acute overdosage of TORECAN (thiethylperazine) can be expected to reflect the CNS effects of the drug and include extrapyramidal symptoms (E.P.S), confusion and convulsions with reduced or absent reflexes, respiratory depression and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Thiethylperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololThiethylperazine may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Alaproclate.Experimental
AlfentanilThiethylperazine may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmagateAlmagate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThiethylperazine may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineThiethylperazine may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololThiethylperazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmodiaquineThe serum concentration of Thiethylperazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Amoxapine.Approved
ArotinololThiethylperazine may increase the hypotensive activities of Arotinolol.Approved
ArtemetherThe serum concentration of Thiethylperazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Thiethylperazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Thiethylperazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Thiethylperazine can be increased when it is combined with Artenimol.Approved
ArtesunateThe serum concentration of Thiethylperazine can be increased when it is combined with Artesunate.Approved
AtenololThiethylperazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Thiethylperazine can be increased when it is combined with Atovaquone.Approved
BefunololThiethylperazine may increase the hypotensive activities of Befunolol.Experimental
BetaxololThiethylperazine may increase the hypotensive activities of Betaxolol.Approved
BevantololThiethylperazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideThiethylperazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololThiethylperazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololThiethylperazine may increase the hypotensive activities of Bopindolol.Approved
BucindololThiethylperazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolThiethylperazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupranololThiethylperazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThiethylperazine may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThiethylperazine may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarfentanilThiethylperazine may increase the hypotensive activities of Carfentanil.Illicit, Vet Approved
CarteololThiethylperazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThiethylperazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThiethylperazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe serum concentration of Thiethylperazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorproguanilThe serum concentration of Thiethylperazine can be increased when it is combined with Chlorproguanil.Investigational
CitalopramThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Citalopram.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Clomipramine.Approved, Vet Approved
CloranololThiethylperazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThiethylperazine may increase the hypotensive activities of Codeine.Approved, Illicit
Cycloguanil embonateThe serum concentration of Thiethylperazine can be increased when it is combined with Cycloguanil embonate.Experimental
DapoxetineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Thiethylperazine can be increased when it is combined with Dapsone.Approved, Investigational
DextromoramideThiethylperazine may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneThiethylperazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThiethylperazine may increase the hypotensive activities of Dezocine.Approved
DihydrocodeineThiethylperazine may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineThiethylperazine may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineThiethylperazine may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiphenoxylateThiethylperazine may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DoxycyclineThe serum concentration of Thiethylperazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThiethylperazine may increase the hypotensive activities of DPDPE.Investigational
EpanololThiethylperazine may increase the hypotensive activities of Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Escitalopram.Approved, Investigational
EsmololThiethylperazine may increase the hypotensive activities of Esmolol.Approved
EthylmorphineThiethylperazine may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtorphineThiethylperazine may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FenfluramineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThiethylperazine may increase the hypotensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluvoxamine.Approved, Investigational
HalofantrineThe serum concentration of Thiethylperazine can be increased when it is combined with Halofantrine.Approved
HeroinThiethylperazine may increase the hypotensive activities of Heroin.Approved, Illicit
HydrocodoneThiethylperazine may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphoneThiethylperazine may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
HydroxychloroquineThe serum concentration of Thiethylperazine can be increased when it is combined with Hydroxychloroquine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Indalpine.Investigational, Withdrawn
IndenololThiethylperazine may increase the hypotensive activities of Indenolol.Withdrawn
KetobemidoneThiethylperazine may increase the hypotensive activities of Ketobemidone.Approved
LabetalolThiethylperazine may increase the hypotensive activities of Labetalol.Approved
LandiololThiethylperazine may increase the hypotensive activities of Landiolol.Investigational
LevobunololThiethylperazine may increase the hypotensive activities of Levobunolol.Approved
Levomethadyl AcetateThiethylperazine may increase the hypotensive activities of Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Levomilnacipran.Approved
LevorphanolThiethylperazine may increase the hypotensive activities of Levorphanol.Approved
LofentanilThiethylperazine may increase the hypotensive activities of Lofentanil.Illicit
LumefantrineThe serum concentration of Thiethylperazine can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MefloquineThe serum concentration of Thiethylperazine can be increased when it is combined with Mefloquine.Approved
MepindololThiethylperazine may increase the hypotensive activities of Mepindolol.Experimental
MeptazinolThiethylperazine may increase the hypotensive activities of Meptazinol.Experimental
MethadoneThiethylperazine may increase the hypotensive activities of Methadone.Approved
Methadyl AcetateThiethylperazine may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MetipranololThiethylperazine may increase the hypotensive activities of Metipranolol.Approved
MetoprololThiethylperazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Milnacipran.Approved
MizoribineThe serum concentration of Thiethylperazine can be increased when it is combined with Mizoribine.Investigational
MorphineThiethylperazine may increase the hypotensive activities of Morphine.Approved, Investigational
NadololThiethylperazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThiethylperazine may increase the hypotensive activities of Nalbuphine.Approved
NicomorphineThiethylperazine may increase the hypotensive activities of Nicomorphine.Experimental
NormethadoneThiethylperazine may increase the hypotensive activities of Normethadone.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Olanzapine.Approved, Investigational
OpiumThiethylperazine may increase the hypotensive activities of Opium.Approved, Illicit
OxprenololThiethylperazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThiethylperazine may increase the hypotensive activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneThiethylperazine may increase the hypotensive activities of Oxymorphone.Approved, Investigational, Vet Approved
ParoxetineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paroxetine.Approved, Investigational
PenbutololThiethylperazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThiethylperazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PethidineThiethylperazine may increase the hypotensive activities of Pethidine.Approved
PhenazocineThiethylperazine may increase the hypotensive activities of Phenazocine.Experimental
PhenoperidineThiethylperazine may increase the hypotensive activities of Phenoperidine.Experimental
PindololThiethylperazine may increase the hypotensive activities of Pindolol.Approved
PiritramideThiethylperazine may increase the hypotensive activities of Piritramide.Investigational
PractololThiethylperazine may increase the hypotensive activities of Practolol.Approved
PrimaquineThe serum concentration of Thiethylperazine can be increased when it is combined with Primaquine.Approved
ProguanilThe serum concentration of Thiethylperazine can be increased when it is combined with Proguanil.Approved
PropranololThiethylperazine may increase the hypotensive activities of Propranolol.Approved, Investigational
PyrimethamineThe serum concentration of Thiethylperazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Thiethylperazine can be increased when it is combined with Pyronaridine.Investigational
QuinacrineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinine.Approved
RadicicolThe serum concentration of Thiethylperazine can be increased when it is combined with Radicicol.Experimental
RemifentanilThiethylperazine may increase the hypotensive activities of Remifentanil.Approved
SertralineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Sertraline.Approved
SinefunginThe serum concentration of Thiethylperazine can be increased when it is combined with Sinefungin.Experimental
SotalolThiethylperazine may increase the hypotensive activities of Sotalol.Approved
SufentanilThiethylperazine may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Thiethylperazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Thiethylperazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
tafenoquineThe serum concentration of Thiethylperazine can be increased when it is combined with tafenoquine.Investigational
TalinololThiethylperazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThiethylperazine may increase the hypotensive activities of Tapentadol.Approved
TertatololThiethylperazine may increase the hypotensive activities of Tertatolol.Experimental
ThiopentalThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Thiopental.Approved, Vet Approved
TilidineThiethylperazine may increase the hypotensive activities of Tilidine.Experimental
TimololThiethylperazine may increase the hypotensive activities of Timolol.Approved
TramadolThiethylperazine may increase the hypotensive activities of Tramadol.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.Approved, Investigational
TrimethoprimThe serum concentration of Thiethylperazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
VilazodoneThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vilazodone.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vortioxetine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Zimelidine.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Maurer H, Pfleger K: Identification of phenothiazine antihistamines and their metabolites in urine. Arch Toxicol. 1988;62(2-3):185-91. [PubMed:2904251 ]
External Links
Human Metabolome Database
HMDB14516
KEGG Drug
D02354
KEGG Compound
C07132
PubChem Compound
5440
PubChem Substance
46506502
ChemSpider
5245
BindingDB
78436
ChEBI
9544
ChEMBL
CHEMBL1378
Therapeutic Targets Database
DAP000315
PharmGKB
PA164748882
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Thiethylperazine
ATC Codes
R06AD03 — Thiethylperazine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)62-64 °CPhysProp
boiling point (°C)227 °C at 1.00E-02 mm HgPhysProp
water solubility0.0584 mg/LNot Available
logP5.41HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00487 mg/mLALOGPS
logP5.12ALOGPS
logP4.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity122.56 m3·mol-1ChemAxon
Polarizability46.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9558
Blood Brain Barrier+0.9847
Caco-2 permeable+0.748
P-glycoprotein substrateSubstrate0.8705
P-glycoprotein inhibitor IInhibitor0.8683
P-glycoprotein inhibitor IIInhibitor0.6434
Renal organic cation transporterInhibitor0.715
CYP450 2C9 substrateNon-substrate0.8381
CYP450 2D6 substrateSubstrate0.7491
CYP450 3A4 substrateNon-substrate0.607
CYP450 1A2 substrateInhibitor0.9159
CYP450 2C9 inhibitorNon-inhibitor0.8968
CYP450 2D6 inhibitorInhibitor0.943
CYP450 2C19 inhibitorNon-inhibitor0.5565
CYP450 3A4 inhibitorNon-inhibitor0.7657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.684
Ames testNon AMES toxic0.885
CarcinogenicityNon-carcinogens0.9366
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5624 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9258
hERG inhibition (predictor II)Inhibitor0.8292
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0000900000-66239882c220302aee87
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0400900000-67c33b4bb0599ec5f25e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-1920000000-8306550db4ba65e81586
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03kc-6960000000-91d197f5c5cc7ac38c4d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0229-9560000000-c669a4875fb62a347fb8

Taxonomy

Description
This compound belongs to the class of chemical entities known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organoheterocyclic compounds
Sub Class
Benzothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Thiophenol ethers / N-methylpiperazines / Alkylarylthioethers / 1,4-thiazines / Trialkylamines / Sulfenyl compounds / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Thiophenol ether / Alkylarylthioether / N-alkylpiperazine / N-methylpiperazine / 1,4-diazinane
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, N-methylpiperazine (CHEBI:9544 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Briani C, Cagnin A, Chierichetti F, Tiberio M, Battistin L, Pizzolato G: Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade. Eur J Neurol. 2004 Oct;11(10):709-10. [PubMed:15469457 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:36